We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+31.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.67B
AUM Growth
+$753M
Cap. Flow
-$209M
Cap. Flow %
-7.82%
Top 10 Hldgs %
54.38%
Holding
380
New
93
Increased
88
Reduced
106
Closed
73

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$10.1M
2
CYTR
CytRx Corp
CYTR
+$5.67M
3
CELG
Celgene Corp
CELG
+$4.08M
4
UTHR icon
United Therapeutics
UTHR
+$3.38M
5
DVAX
Dynavax Technologies
DVAX
+$3.33M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$7.47M
2
ABT icon
Abbott
ABT
+$6.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.84M
4
NVIV
InVivo Therapeutics Holdings Corp
NVIV
+$3.87M
5
AMGN icon
Amgen
AMGN
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 9.24%
2 Consumer Staples 0.04%
3 Technology 0.03%
4 Industrials 0.01%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
101
DELISTED
La Jolla Pharmaceutical Company
LJPC
$2.88M 0.11%
120,964
-85,167
-41% -$1.6M
PVLA
102
Palvella Therapeutics
PVLA
$2.05B
$2.82M 0.11%
19,291
-909
-5% -$121K
TSRO
103
DELISTED
TESARO, Inc.
TSRO
$2.76M 0.1%
+27,500
New +$2.57M
IONS icon
104
PUT
Ionis Pharmaceuticals
IONS
$8.93B
$2.7M 0.1%
737
-247
-25% -$7.73K
OPK icon
105
CALL
Opko Health
OPK
$1.02B
$2.64M 0.1%
2,491
+1,000
+67% +$9.96K
SGMO
106
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.6M 0.1%
5,611
+1,211
+28% +$6.16K
THC icon
107
Tenet Healthcare
THC
$22.2B
$2.56M 0.1%
+112,831
New +$2.94M
GWPH
108
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.55M 0.1%
+192
New +$18.4K
REGN icon
109
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$2.53M 0.09%
63
+20
+47% +$8.02K
DRRX
110
DELISTED
DURECT Corp
DRRX
$2.5M 0.09%
180,000
-74,028
-29% -$1.22M
EXEL icon
111
CALL
Exelixis
EXEL
$13.9B
$2.47M 0.09%
1,930
+147
+8% +$1.59K
DERM
112
CALL
DELISTED
Dermira, Inc.
DERM
$2.44M 0.09%
722
+310
+75% +$9.98K
HCA icon
113
PUT
HCA Healthcare
HCA
$88.4B
$2.39M 0.09%
316
+216
+216% +$16.5K
SPHS
114
DELISTED
Sophiris Bio, Inc.
SPHS
$2.35M 0.09%
+757,033
New +$2.85M
ABT icon
115
CALL
Abbott
ABT
$187B
$2.35M 0.09%
555
– –
DERM
116
PUT
DELISTED
Dermira, Inc.
DERM
$2.29M 0.09%
678
+389
+135% +$12.5K
PRTK
117
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.28M 0.09%
175,000
-130,964
-43% -$1.74M
VRTX icon
118
PUT
Vertex Pharmaceuticals
VRTX
$123B
$2.27M 0.08%
260
– –
VXZ
119
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$2.21M 0.08%
65,000
– –
ENDP
120
PUT
DELISTED
Endo International plc
ENDP
$2.21M 0.08%
+1,096
New +$21.8K
CDTX
121
DELISTED
Cidara Therapeutics
CDTX
$2.18M 0.08%
9,518
+8,504
+839% +$1.97M
ALPN
122
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.18M 0.08%
66,913
-93,460
-58% -$2.28M
OPK icon
123
PUT
Opko Health
OPK
$1.02B
$2.15M 0.08%
2,027
-618
-23% -$6.15K
ARAV
124
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.14M 0.08%
+29,161
New +$2.11M
EXAS
125
PUT
DELISTED
Exact Sciences
EXAS
$2.14M 0.08%
+1,153
New +$20.3K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sabby Management held 380 positions worth $2.67B, up 39% from $1.92B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sabby Management withdrew a net $209M in Q3 2016, closing 73 positions and reducing 106 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $4.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, down from 13% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Sabby Management opened a new position in Bristol-Myers Squibb worth $8.46M.

  • Sabby Management's largest Q3 2016 buy was Bristol-Myers Squibb: 156,887 shares worth $8.46M.
  • Sabby Management added most to Dynavax Technologies in Q3 2016, an estimated $3.33M increase.
  • Sabby Management's biggest Q3 2016 reduction was Sarepta Therapeutics, cutting an estimated $7.47M.
  • Sabby Management fully exited Global Blood Therapeutics, Inc. in Q3 2016, selling an estimated $4.84M.
  • Sabby Management's ten largest holdings make up 54% of its $2.67B portfolio in Q3 2016.
  • Sabby Management opened 93 new positions and closed 73 in Q3 2016.
  • Sabby Management's portfolio value rose 39% quarter-over-quarter to $2.67B.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.